Celgene pays $450M to share MEDI4736 with AZ

Celgene Corp. (NASDAQ:CELG) and the MedImmune LLC unit of AstraZeneca plc (LSE:AZN; NYSE:AZN) entered an exclusive collaboration agreement to develop AZ's MEDI4736, a human IgG1 mAb targeting PD-L1 to treat blood cancers.

Celgene intends to evaluate MEDI4736 to treat non-Hodgkin's lymphoma (NHL), multiple myeloma (MM) and myelodysplastic syndromes (MDS), and plans to begin its first clinical study of the candidate next half. The partners said they plan to test MEDI4736 in combination with both companies' approved and investigational cancer therapies. ...